• Globus Medical reported second quarter fiscal 2026 adjusted EPS of $1.34, ahead of analyst estimates, with $790 million in revenue that was slightly below consensus, while earnings exceeded expectations in each of the past four quarters.
• The pattern of earnings surprises and an estimated long term earnings growth rate of 12.4% highlights how Globus Medical’s operating model and cost structure are supporting profitability even when top line results track close to forecasts.
• This analysis explores how Globus Medical's investment narrative is affected by this consistent earnings outperformance, particularly the strong adjusted EPS beat.

Spot patterns in Globus Medical's earnings surprise and see how similar profit focused stories line up in our hand picked 30 high quality undervalued stocks.

Globus Medical Investment Narrative Recap

To own Globus Medical, you need to be comfortable with a story built around consistent profit generation, efficient manufacturing and disciplined use of cash rather than rapid top line acceleration. The latest quarter, where adjusted EPS outpaced expectations despite revenue sitting close to forecasts, fits neatly into that earnings-first view of the business.

The key near term swing factor is whether Excelsius robotics, trauma and international spine can keep absorbing volatility in Enabling Technologies and the Nevro reset. Pricing pressure from hospitals and payers, along with any missteps integrating past acquisitions, remains the biggest operational risk and is more important to watch than this single quarter’s modest revenue miss.

The most relevant recent development is the pattern of earnings surprises. Globus Medical has exceeded EPS expectations in each of the past four quarters, with an average beat of 27.88%. The latest 19.6% upside to the consensus EPS estimate reinforces a picture of tight cost control and productive use of the Excelsius ecosystem and broader musculoskeletal platform.

For catalysts, that track record matters because it sits alongside reported adjusted gross margins in the high 60s and adjusted EBITDA margins in the mid 30s. If management continues to convert Excelsius deployments, trauma expansion and international growth into steady EPS gains, while managing Nevro volatility and reimbursement pressure, the existing profit profile remains central to how investors frame Globus Medical today.

Globus Medical's current earnings of $535.4 million are set against analyst expectations for earnings of $767.4 million by 2029. This implies an earnings increase of about $232 million and aligns with forecasts for 5.8% yearly revenue growth and projected revenue of $3.7 billion in the same year.

Uncover why Globus Medical's fair value indicates a 22% potential upside to its current price, which could close faster than investors expect.

Exploring Other Perspectives

Some of the most optimistic analysts focus on Globus Medical’s shift toward leases in Enabling Technologies as a potential accelerator. Before this EPS beat, they were already modeling about US$3.8b in revenue and US$873.0m in earnings by 2029. That is a far more upbeat script than consensus, and this latest quarter may nudge those storylines in new directions.

Explore 5 other Globus Medical fair value estimates, including one that suggests as much as 113% potential upside from the current price.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.

• A great starting point for your Globus Medical research is our analysis highlighting 5 key rewards that could impact your investment decision.
• See our latest analysis for Globus Medical. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Globus Medical's overall financial health at a glance.

Looking for more Globus Medical style investment ideas?

Globus Medical’s profit focused story is just one example of how earnings quality, balance sheet strength and cash generation can shape an investment thesis. If you want to broaden your watchlist with other stocks that share some of these traits, the Simply Wall St Screener can help you surface ideas that fit your own preferences on value, risk and income.

• For investors who want quality and value to work together, consider reviewing our curated 30 high quality undervalued stocks that pair solid fundamentals with prices below many analyst expectations.
• If capital preservation and steadier profiles matter most to you, filter for companies in the 30 resilient stocks with low risk scores and see which businesses score well on financial resilience.
• When the goal is to back under followed opportunities before they become crowded trades, scan through the 18 high quality undiscovered gems and spot lesser known stocks with robust underlying metrics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.